Global Sacituzumab Tirumotecan Market Strategic Research Report

Scope of the Report

The global Sacituzumab Tirumotecan market size is predicted to grow from US$ 196 million in 2025 to US$ 938 million in 2032; it is expected to grow at a CAGR of 17.7% from 2026 to 2032.

Sacituzumab Tirumotecan is an antibody–drug conjugate (ADC) targeting trophoblast cell-surface antigen 2 (TROP-2). It consists of a humanized monoclonal antibody, a cleavable linker, and a cytotoxic payload. The antibody component specifically recognizes and binds to the TROP-2 antigen expressed on tumor cells, enabling the targeted delivery of the cytotoxic agent into the cells, where the active component is released to inhibit DNA replication and induce cell death. This drug is mainly used for the targeted treatment of various solid tumors, such as breast cancer and lung cancer. It is characterized by high targeting specificity, strong cytotoxic efficacy, and relatively controllable systemic toxicity, making it an important innovative therapy in the field of antibody–drug conjugates.In 2025, global sacituzumab tirumotecan production reached approximately 1.2 million units.

Sacituzumab Tirumotecan, as a TROP-2-targeting antibody–drug conjugate (ADC), is in a rapid growth phase within the precision oncology market. With the rising incidence of high-prevalence solid tumors such as breast cancer and lung cancer, along with the increasing demand for targeted therapies, this drug is gradually gaining clinical recognition and driving market expansion due to its advantages of “high targeting specificity and potent cytotoxicity.” Meanwhile, the maturation of ADC technology platforms and supportive policies for innovative drugs have also facilitated its commercialization. However, market competition is intensifying, including from products with the same target (such as Trodelvy) as well as other ADC drugs (such as Enhertu), which pose direct competitive pressure. Overall, the market for Sacituzumab Tirumotecan represents a “high-value, fast-growing” segment of innovative therapeutics, with future growth mainly driven by indication expansion, global market development, and continuous validation of clinical data.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Sacituzumab Tirumotecan market?

What factors are driving Sacituzumab Tirumotecan market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Sacituzumab Tirumotecan market opportunities vary by end market size?

How does Sacituzumab Tirumotecan break out by Type, by Application?

This report presents a comprehensive overview of the global Sacituzumab Tirumotecan market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Monoclonal Antibody, mAb
• Bispecific Antibody, bsAb

Segment by Specification

• 60 mg/vial
• 120 mg/vial

Segment by Production Technology

• Innovator
• Generic

Segment by Dosage Form

• Lyophilized Powder for Injection
• Injection Solution

Segment by Application

• Breast Cancer
• Lung Cancer
• Digestive System Tumors
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Sacituzumab Tirumotecan market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Breast Cancer, Lung Cancer, Digestive System Tumors evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact